Long-term survival and AI-based prediction in NSCLC patients treated with immunotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective, multicenter observational study of patients with advanced or locally advanced NSCLC who received checkpoint inhibitors alone or with combinations. The goal is to define real-world long-term vs short-term survival cohorts and to characterize multi-omics landscapes. The study also aims to develop and validate an AI pathologic prediction model using standard H&E images to forecast immune features and long-term outcomes after immunotherapy. Data will come from multiple centers and, when applicable, completed phase III trials. Analysis will focus on patients with complete clinical information and adequate follow-up.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with pathologically confirmed advanced or locally advanced non-small cell lung cancer (NSCLC).
* Patients derived from real-world data of multiple centers (including Cancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital of Shanxi, Chinese Academy of Medical Sciences \[Shanxi Cancer Hospital\]; and other participating centers) or from completed phase III clinical trials (e.g., Choice-01, Rationale-307, Rationale-304).
* Patients who received first-line or later-line immune checkpoint inhibitor (ICI) monotherapy or ICI-based combination therapy.
* Patients with complete clinical information and available follow-up data.

Exclusion Criteria:

* Patients whose systemic therapy did not include an immunotherapy regimen.
* Patients lost to follow-up.

Where it's running

• Cancer Hospital Chinese Academy of Medical Sciences
  Beijing, China Recruiting

Study contacts

• Principal investigator: Jie Wang, MD, PhD — Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• Study coordinator: Jie Wang, MD,PhD
• Email: zlhuxi@163.com
• Phone: 8610-87788029

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC

  This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07894458

• PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer

  This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT07884877

• FAPI-guided radiotherapy with cadonilimab plus chemo for colorectal cancer limited to the peritoneum

  Aims to see if adding targeted radiotherapy and cadonilimab immunotherapy to standard second-line chemotherapy helps adults with colorectal cancer that’s spread only to the peritoneum.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07815834

• Imaging study of [68Ga]Ga-DWJ155 in adults with solid tumors

  This trial tests a new radioligand imaging agent, [68Ga]Ga-DWJ155, to see how well it images tumors and how safe it is in adults with advanced solid cancers.

  Recruiting at 2 sites Phase 1 Novartis · Darlinghurst, New South Wales and 1 other locations · NCT07801508

• Quality of life during adjuvant immunotherapy for locally advanced non-small cell lung cancer

  This study looks at how patients feel and cope during a year of immunotherapy after chemoradiotherapy for locally advanced non-small cell lung cancer.

  Recruiting Göteborg University · Gothenburg · NCT07754409

• Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in Localized Rectal Cancer

  In people with locally advanced, treatment-naive rectal cancer, this study tests whether adding two immunotherapy drugs to a standard chemotherapy after short-course radiotherapy can improve tumor response.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07686640

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.